ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 0601 • ACR Convergence 2025

    Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review

    Ali Ardekani1, Alain Sanchez-Rodriguez2, Mariana González-Treviño3, Jose Meade-Aguilar4, Maria O. Valenzuela-Almada5, Hannah Langenfeld1, Larry J. Prokop4, Isabel Valenzuela Almada6, Gabriel Figueroa-Parra7, Nicolás Sánchez Domínguez8, Alejandro A. Rabinstein4, M. Hassan Murad4, Cynthia Crowson9 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2ABC Medical Center, Ciudad de México, Federal District, Mexico, 3Vanderbilt University Medical Center, Nashville, 4Mayo Clinic, Rochester, 5Children’s National Medical Center, Washington D.C, 6Universidad Panamericana, Ciudad de México, Federal District, Mexico, 7Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 8Clínica Alemana de Santiago, Santiago, Chile, 9Mayo Clinic, Stewartvillle, MN

    Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is an underrecognized neuroradiologic complication of SLE, characterized by acute neurological symptoms and vasogenic edema on neuroimaging. Its precipitating…
  • Abstract Number: 0806 • ACR Convergence 2025

    Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation

    Teng-Chieh Hsu1, An-Ping Huo2, Pei-Lun Liao2, Pui-Ying Leong2 and James Wei3, 1Wuri Lin Shin Hospital, Taichung, Taiwan (Republic of China), 2Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), 3Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China)

    Background/Purpose: Anifrolumab and belimumab are biologic agents approved for systemic lupus erythematosus (SLE), yet their comparative safety profiles, particularly regarding infection risks, remain inadequately characterized…
  • Abstract Number: 0363 • ACR Convergence 2025

    Assessing Whole Health Needs in Systemic Lupus Erythematosus

    Amanda Eudy1, Megan Clowse2, Dana Burshell3, Connor Drake3, Tamara Somers4, David Pisetsky5, Rebecca Sadun6, Ralph Snyderman7, Kai Sun6, Lisa Criscione-Schreiber3, Mithu Maheswaranathan3, Nathaniel Harris5, Jayanth Doss8 and Jennifer Rogers3, 1Duke University, Raleigh, NC, 2Duke University, Chapel Hill, NC, 3Duke University School of Medicine, Durham, 4Duke University School of Medicine, Durham, NC, 5Duke University Medical Center, Durham, NC, 6Duke University, Durham, NC, 7Duke Center for Personalized Health Care, Durham, NC, 8Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC

    Background/Purpose: Care models that take a ‘Whole Health’ perspective by emphasizing personalized care focused on the individual’s values, needs, and goals, rather than solely on…
  • Abstract Number: 0119 • ACR Convergence 2025

    Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus

    Elizabeth Sloan1, Blake Baay2, Lynnette Walters2, Paola Sparagana2, Kristina Ciaglia1, Simrat Morris1, Julie Fuller1, Lorien Nassi1, Tracey Wright1 and Ayesha Zia3, 1UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, 2Scottish Rite for Children, Dallas, TX, 3UT Southwestern and Children's Medical Center, Dallas, TX

    Background/Purpose: In pediatric systemic lupus erythematosus (SLE), antiphospholipid antibodies (aPL) are independent risk factors for thrombosis. However, data are limited on how aPL impact hypercoagulability.…
  • Abstract Number: 2632 • ACR Convergence 2025

    Maternal vascular malperfusion: association with adverse perinatal outcomes in lupus pregnancies

    ANA JIMENA LOPEZ DIAZ1, MARIA DEL CARMEN ZAMORA MEDINA2, Mario Isaac Lumbreras Márquez1, Diana Yazmin Copado mendoza1, Oralia Alejandra Orozco Guillén1, Maria José rodríguez Sibaja1, Martha Leticia Palafox Vargas1 and Sandra Acevedo gallegos1, 1Instituto Nacional de Perinatología, Mexico City, Distrito Federal, Mexico, 2Instituto Nacional de Perinatologia, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of adverse perinatal outcomes (APOs), including preeclampsia, preterm birth, fetal growth restriction, and stillbirth. Placental…
  • Abstract Number: 2547 • ACR Convergence 2025

    Assessing the Reach of a Virtual Education Program: Lupus & You: Answers. Advocacy. Action.

    Ashley Holden, Wendy Rodgers, Khadija Dantata, Lety Ocana and Guadalupe Patino, The Lupus Foundation of America, Washington, DC

    Background/Purpose: Comprehensive lupus education is essential for increasing awareness, early diagnosis and management of lupus due to the disease’s heterogenous nature. The Lupus Foundation of…
  • Abstract Number: 2454 • ACR Convergence 2025

    Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy

    Jonatan Tuncel1, Trever Greene2, Nicholas Brookhouser2, Sandeep Kothapally Hanok1, Seth Peng1, Alison O’Conor1, Parastoo Fazeli3, Jennifer Medlin4, Cara Bickers2, Kelsea Hubka1, Allison Aguilar1, Wei Zhao1, Kyla Omilusik1, John Goulding1, Tom Lee2, Jode Goodridge2, Marie Hu5, Veronika Bachanova5, Jeffrey Miller6, Matthew Lunning7, Rebecca Elstrom2, Debra Zack1, Vaneet Sandhu2, Bahram Valamehr8 and Lilly Wong8, 1Fate Therapeutics, San Diego, 2Fate Therapeutics, Inc., San Diego, 3UMN, ST PAUL, MN, 4University of Nebraska Medical Center, Omaha, NE, 5University of Minnesota, Minneapolis, 6University of Minnesota, Minneaspolis, MN, 7University of Nebraska Medical Center, Omaha, 8Fate Therapeutics, Inc., San Diego, CA

    Background/Purpose: Autologous chimeric antigen receptor (CAR) T-cell therapy is an exciting new potential therapy for autoimmune diseases but limited in scope of application by logistical…
  • Abstract Number: 2437 • ACR Convergence 2025

    Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis

    Aaron Smith1, Thuyvan Phan2, Leah Luizza3, Anthony Trujillo3, Becki Cleveland1, Shruti Saxena Beem4, Tessa Englund5, Claire Timon4 and Saira Sheikh5, 1University of North Carolina, Chapel Hill, NC, 2UNC Health, Chapel Hill, NC, 3University of North Carolina, Chapel Hill, 4University of North Carolina at Chapel Hill, Chapel Hill, 5University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multi-system autoimmune disease with heterogenous presentation. Most patients with SLE report fatigue or brain fog, which often…
  • Abstract Number: 2418 • ACR Convergence 2025

    ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin

    Mehrnaz Gharaee-Kermani1, Svenja Henning2, John LaCava3, Tomas Mustelin4 and J. Michelle Kahlenberg1, 1University of Michigan, Ann Arbor, MI, 2University of Groningen, Groningen, Groningen, Netherlands, 3Rockefeller University, New York City, NY, NJ, 4University of Washington, Seattle, WA

    Background/Purpose: Type I interferons (IFNs) are elevated in the skin and blood of patients with systemic (SLE) and cutaneous (CLE) lupus erythematosus. Upregulation of type…
  • Abstract Number: 2402 • ACR Convergence 2025

    High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment

    Alexander Tsoi1, Dionysis Nikolopoulos2, Natalia Sherina3 and Ioannis Parodis1, 1Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, 2Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 3Karolinska Institutet, Division of Rheumatology, Department of Medicine Solna, and Karolinska University Hospital, Stockholm, Stockholm, Stockholms Lan, Sweden

    Background/Purpose: Belimumab, a BAFF inhibitor, is an effective treatment for systemic lupus erythematosus (SLE), but biomarkers predicting treatment response remain elusive. We aimed to identify…
  • Abstract Number: 2384 • ACR Convergence 2025

    Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort

    Bernard Rubin1, Rou Sore1, Melissa Munroe1, Daniele DeFreese1, Adrian Holloway1, Mohan Purushothaman1, Yangfen Li2, Hu Zeng2, Uma Thanarajasingam2, Judith James3 and Eldon Jupe1, 1Progentec Diagnostics, Inc., Oklahoma City, OK, 2Mayo Clinic, Rochester, MN, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by unpredictable disease activity. The Lupus Disease Activity Index (L-DAI) is a blood-based assessment…
  • Abstract Number: 2215 • ACR Convergence 2025

    Placenta Abnormalities in Systemic Lupus Erythematosus: Novel Marker of Adverse Pregnancy Outcomes

    Kaitlin Nuechterlein1, Karl Grenier1, Luisa Ciofani2, Kalliopi Panaritis2, Sasha Bernatsky2 and Evelyne Vinet2, 1McGill University, Montreal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Placenta-mediated adverse pregnancy outcomes (APO) are a huge concern in SLE. Recent efforts to understand APO include the establishment of the 2016 Amsterdam classification…
  • Abstract Number: 1975 • ACR Convergence 2025

    Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project

    Cristine Kuzhuppilly Arcilla1, Gabriel Kirsch2, Gurjit Kaeley3 and Myint Thway4, 1University of Florida Jacksonville, Jacksonville, FL, 2University of Florida - Jacksonville, Jacksonville, FL, 3UF COM-J, Ponte Vedra Beach, FL, 4UF Jacksonville, ponte vedra, FL

    Background/Purpose: In 2017, FDA approved warnings regarding fatal cardiac effects such as cardiomyopathy, torsades de pointes, and QTc prolongation related to both acute and chronic…
  • Abstract Number: 1853 • ACR Convergence 2025

    SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.

    Yevgeniya Gartshteyn1, Daniel Portnoy2, Matthieu Paiola3, Anca Askanase2 and Adam Mor4, 1Columbia University Medical Center, Glen Rock, NJ, 2Columbia University Medical Center, New York, NY, 3Columbia University Irving Medical Center, New York, NY, 4Columbia University, New York, NY

    Background/Purpose: SAP is an adaptor protein that mediates signaling downstream of SLAMF T cell receptors. SAP deficiency results in X-linked Lymphoproliferative immunodeficiency characterized by impaired…
  • Abstract Number: 1834 • ACR Convergence 2025

    Integrative Bioinformatics Analysis Reveals Key Genes and Immune Profiles Associated with Preeclampsia in Lupus Pregnancy

    Rodolfo Martinez-Canales1, Eva Abigaid Galindo-Calvillo2, Andres M. Ortiz-Rios2, Braulio R. Avalos-Garcia2, Lorena Perez-Barbosa2, Dionicio A. Galarza-Delgado3, Cassandra Michele Skinner-Taylor2, Mario Cesar Salinas-Carmona1 and Noe Macias-Segura1, 1Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico

    Background/Purpose: Preeclampsia (PE) is a serious complication of pregnancy associated with significant maternal and fetal outcomes. Systemic lupus erythematosus (SLE) significantly increases the risk of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology